cutaneous lupus erythematosus

Povorcitinib phosphate is a selective JAK1 inhibitor and can be used in studies about the treatment of cutaneous lupus erythematosus and Lichen planus.

Povorcitinib is a highly potent and selective JAK1 inhibitor with significant potential for the investigation of cutaneous lupus erythematosus (CLE) and Lichen planus (LP).

PAD-IN-2, a potent inhibitor of PAD4 with an IC50 value <1 μM, can be utilized to study autoimmune diseases and cancers, including rheumatoid arthritis, vasculitis, systemic lupus erythematosus, cutaneous lupus erythematosus, cystic fibrosis, ulcerative colitis, asthma, multiple sclerosis, and psoriasis.

The immunoregulator spleen tyrosine kinase (SYK) is upregulated in cutaneous lupus erythematosus (CLE). This double-blind, multicentre, Phase Ib study evaluated the safety, tolerability, pharmacokinetics, pharmacodynamics and clinical efficacy of the selective SYK inhibitor GSK2646264 in active CLE lesions

Prezalumab (AMG 557) is a human IgG2 monoclonal antibody targeting ICOSL and BAFF, used for studying Sjogren's syndrome, cutaneous lupus erythematosus, psoriasis, systemic lupus erythematosus arthritis, and systemic lupus erythematosus (SLE).

Litifilimab (BIIB059) is a humanizedantibody targeting the plasma cell-like dendritic cell specific antigen (BDCA2) and C-type lectin structural domain family 4, member C (CLEC4C) for the study of cutaneous lupus erythematosus.